Barclays PLC vs Stryker Corporation — how do they compare? Barclays PLC trades at $28.11 (market cap $93.87B), while Stryker Corporation trades at $345.73 (market cap $133.54B). The key difference: Stryker Corporation is the larger of the two by market cap, and Barclays PLC pays the higher dividend (2.19%). Which is the better fit depends on your goals.
| BCS | SYK | |
|---|---|---|
Market Cap | $93.87B | $133.54B |
Sector | Financials | Technology |
52-Week High | $28.56 | $394.34 |
52-Week Low | $19.36 | $282.58 |
Dividend Yield | 2.19% | 1.01% |
Enterprise Value | — | $145.01B |
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $28.08, up 0.36% today, with a bullish technical signal from moving averages and a P/B ratio below 1 at 0.88, indicating potential undervaluation. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.90 surpassing the $0.89 estimate, while revenue growth accelerated to $29.14 billion in 2025. However, the stock faces headwinds from a securities class action investigation and concerns over cost pressures highlighted in recent analyst reports.
The outlook for BCS is cautiously optimistic, supported by strong profitability with a net income margin of 25.51% and analyst consensus favoring Buy ratings (68%). Key risks include ongoing legal scrutiny and rising operating expenses, but the stock's low valuation and dividend yield near 1.1% offer value for long-term investors amid stable cash flow trends.
Stryker (SYK) trades at $345.86, up slightly by 0.01% today, with a bullish technical signal and strong analyst support. The company reported a Q2 2026 earnings beat with $3.69 EPS versus $3.49 expected, driven by 9% organic sales growth and recovery from a cyber incident. Fundamentals show robust profitability with a 14.43% net income margin and 16.51% ROE, though valuation ratios like a P/E of 36.08 are elevated.
Outlook remains positive with raised guidance and new product launches like Mako RPS expanding market reach. Key risks include execution challenges post-cyberattack and competitive pressures. The consensus price target of $379.44 implies ~10% upside, supported by 74% buy ratings from analysts.
Trailing returns across standard periods
Latest headlines on both assets
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →